for disease activity compared with bedside clinical assessments. Constantly changing conditions in the laboratory, such as variations in temperature, etc., materially affect assay results. Therefore assay result A performed at time 1 cannot accurately be compared with assay result B performed at a different time. Scientific experimental methods would require samples A and B to be performed in the same assay for comparative purposes. In such an experiment using stored samples collected in a prospective MG treatment trial, a fall in antibody titres correlated weakly with improvement as assessed by two validated clinical outcome measures. [5] This study also compared serial measurements of AChR titres in an observational cohort performed at least 6 months apart and at separate times, and found even less correlation between clinical improvement and change in titres. Indeed, the conclusion was that a clinical assessment tool provided a more effective measure to monitor response to therapy. The MG composite score is a good example of a simple clinical tool that can be used to monitor patients. It is a validated instrument that takes 5 minutes to perform, and includes ocular, bulbar, respiratory and proximal muscle strength evaluations. [6] The bulbar and respiratory items are largely based on patient symptoms. In contrast, each commercial AChR antibody test costs ~ZAR1 000.
In conclusion, our recent work suggests that the overall incidence rate of MG in our population is comparable with rates reported in North American and European studies in keeping with a biological rather than environmental aetiology for MG. The geographical variation of the incidence rate within the country underscores the importance of outreach programmes in regions with limited resources. Finally, when managing a chronic disease such as MG, it is preferable to treat the patient's symptoms rather than rely on an expensive laboratory test that cannot be accurately interpreted outside a rigorous scientific experiment. 
